Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effect of Carvedilol on Survival in Severe Chronic Heart Failure

Open access
Packer, Milton, Coats, Andrew J.S., Fowler, Michael B., Katus, Hugo A., Krum, Henry, Mohacsi, Paul, Rouleau, Jean L., Tendera, Michal, Castaigne, Alain, Roecker, Ellen B., Schultz, Melissa K., Staiger, Christoph, Curtin, Ellen L., DeMets, David L. · 2001 · New England Journal of Medicine

Abstract

BACKGROUND: Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure. METHODS: We evaluated 2289 patients who had symptoms of heart failure at rest or on minimal exertion, who were clinically euvolemic, and who had an ejection fraction of less than 25 percent. In a double-blind fashion, we randomly assigned 1133 patients to placebo and 1156 patients to treatment with carvedilol for a mean period of 10.4 months, during which standard therapy for heart failure was continued. Patients who required intensive care, had marked fluid retention, or were receiving intravenous vasodilators or positive inotropic drugs were excluded. RESULTS: There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent decrease in the risk of death with carvedilol (95 percent confidence interval, 19 to 48 percent; P=0.00013, unadjusted; P=0.0014, adjusted for interim analyses). A total of 507 patients died or were hospitalized in the placebo group, as compared with 425 in the carvedilol group. This difference reflected a 24 percent decrease in the combined risk of death or hospitalization with carvedilol (95 percent confidence interval, 13 to 33 percent; P<0.001). The favorable effects on both end points were seen consistently in all the subgroups we examined, including patients with a history of recent or recurrent cardiac decompensation. Fewer patients in the carvedilol group than in the placebo group withdrew because of adverse effects or for other reasons (P=0.02). CONCLUSIONS: The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm200105313442201

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Research works printed but not linked: 8

  1. Domanski MJ, 2000, J Am Coll Cardiol, 35, 202A
  2. Lechat P, 2000, Eur Heart J, 21, 297
  3. Sackner-Bernstein J, 1995, Circulation, 92, I
  4. Qin F, 2000, J Am Coll Cardiol, 35, 168A
  5. 10.2307/2281868 · doi:10.2307/2281868 · Paper page
  6. Weyl JD, 1985, Arch Int Pharmacodyn Ther, 275, 4
  7. Willette RN, 1999, J Pharmacol Exp Ther, 289, 48
  8. Grupp IL, 1998, Am J Physiol, 275, H1338

Cited by

See all 3,093

Metadata

Authors
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., Schultz, M. K., Staiger, C., Curtin, E. L., & DeMets, D. L.
Affiliations
  • Columbia University (US)
  • Royal Brompton Hospital (GB)
  • Stanford Medicine (US)
  • University of Lübeck (DE)
  • Monash University (AU)
  • Mount Sinai Hospital (CA)
  • Hôpitaux Universitaires Henri-Mondor (FR)
  • University of Wisconsin–Madison (US)
Venue
New England Journal of Medicine
Published
2001-05-31
Volume
344
Issue
22
Pages
1651-1658
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3023522280
Cited by
3,093
References
26
Citations by year
2026: 53 · 2025: 57 · 2024: 47 · 2023: 84 · 2022: 92 · 2021: 92 · 2020: 84 · 2019: 91 · 2018: 80 · 2017: 110 · 2016: 112 · 2015: 114 · 2014: 95 · 2013: 106 · 2012: 131
FWCI
156.75
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
carvedilol, chronic heart failure, severe heart failure, beta-blockers, mortality, hospitalization, ejection fraction, acute decompensated heart failure, adverse effects
MeSH terms
Carvedilol, Adrenergic beta-Antagonists, Aged, Carbazoles, Chronic Disease, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Propanolamines, Prospective Studies, Risk, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Carvedilol on Survival in Severe Chronic Heart Failure. https://app.cochat.ai/papers/10.1056/nejm200105313442201
The paper
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., Schultz, M. K., Staiger, C., Curtin, E. L., & DeMets, D. L. (2001). Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejm200105313442201

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.